Drug Profile
Losatuxizumab vedotin - AbbVie
Alternative Names: ABBV-221Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Epidermal growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
- No development reported Solid tumours
Most Recent Events
- 26 Oct 2022 Preclinical trials in Glioblastoma in USA (Infusion), prior to October 2022
- 26 Oct 2022 Pharmacokinetics and adverse event data from a preclinical trial in Glioblastoma presented at the 34th EORTC-NCI-AACR Symposium (ENA-2022)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Taiwan (IV, Infusion)